

ESMO Preceptorship Programme

Colorectal Cancer

Multidisciplinary management, standards of care and future perspectives

Valencia, Spain

20-21 May 2016

CO-CHAIRS: Jean-Yves Douillard, France
Andrés Cervantes, Spain

SPEAKERS: Dirk Arnold, Portugal
Michel Ducreux, France
Pompiliu Piso, Germany
Hans-Rudolf Raab, Germany
Mark Saunders, United Kingdom
Frédéric Bibeau, France

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, side-effects of treatments, and in special situations

May 20th 2016

09:00-9:15 15'	Welcome and introduction	Jean-Yves Douillard, FR Andrés Cervantes, ES
09:15 -10:50 95'	Session 1 Early colorectal cancer	Chair: Pompiliu Piso, DE
30'	The point of view of the pathologist - Quality and rules of a good pathology report - Histo-prognostic factors: Number of Lymph nodes, neural/lymphatic invasion, lymphocytic infiltration, MSH expression	Frédéric Bibeau, FR
20'	State-of-the-art: Standard of surgical practice for resectable colorectal cancer (special issues on rectal cancer)	Hans-Rudolf Raab, DE
30'	State-of-the-art: Standard(s) of radio/chemotherapy for rectal cancer	Mark Saunders, UK
15'	Adjuvant chemotherapy of rectal cancer	Andrés Cervantes, ES
10:50-11:10	Coffee Break	

11:10-13:10 120'	Session 2 Adjuvant settings of colorectal cancer	Chair: Jean-Yves Douillard, FR
30'	Microsatellite instability and other molecular markers – how useful are they?	Frédéric Bibeau, FR
30'	Adjuvant treatment for colon cancer III	Dirk Arnold, PT
30'	Adjuvant treatment of stage II: which patients to treat?	Jean-Yves Douillard, FR
30'	Three cases to be discussed by participants	All Faculty

13:10-14:10	Lunch	
-------------	-------	--

14:10-16:10 120'	Session 3 Metastatic colorectal cancer, liver limited metastases	Chair: Pompiliu Piso, DE
15'	Review of the ESMO consensus conference on metastatic colorectal cancer - Basic strategies and groups (RASwt /mut, BRAF mut)	Dirk Arnold, PT
15'	Development of conventional chemotherapy in mCRC, BSC vs, Chemo, biochemical modulation, oral fluoropyrimidines, development of combination chemotherapy	Jean-Yves Douillard, FR
30'	Resection of liver limited metastasis (Resectable cases, Group 0) - Upfront - After neo-adjuvant treatment - Repeated hepatectomy	Hans-Rudolf Raab, DE
30'	Unresectable or borderline resectable (Group 1) chemotherapy +/- targeted agents	Andrés Cervantes, ES
30'	Three clinical Cases to be discussed by participants	All Faculty

16:10-16:40	Coffee Break	
-------------	--------------	--

16:40-18:10 90'	Session 4 Special clinical situations: Mono- or oligometastatic disease	Chair: Andrés Cervantes, ES
30'	Treatment of metastatic disease confined to the peritoneum - Resection - HIPEC - PIPEC	Pompiliu Piso, DE
30'	Primary with synchronous metastases	Hans-Rudolf Raab, DE
30'	Chemotherapy and targeted agents in 1 st line	Jean-Yves Douillard, FR

Time 20:00	Dinner	
------------	--------	--



GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

May 21st 2016

08:30-09:45 75'	Session 5 Metastatic colorectal cancer I	Chair: Jean-Yves Douillard, FR
50'	The role of maintenance, appropriate endpoints according to ESMO consensus	Michel Ducreux, FR
25'	What to do after 1 st line failure	Dirk Arnold, PT

9:45-10:15	Coffee Break
------------	--------------

10:15-11:45 90'	Session 6 Metastatic colorectal cancer II	Chair: Andrés Cervantes, ES
30'	Options of locoregional treatment of liver metastasis - Intra-arterial therapy - Chemo-embolisation - SIRT Local radiation	Michel Ducreux, FR
30'	Management of treatment related side effects - GI-Toxicity - Neuropathy - Skin toxicity - Hypertension - Hand-foot syndrome	Michel Ducreux, FR
30'	Three cases to be discussed by participants	All Faculty

11:45-12:30 45'	Session 7 Anal Canal tumors	Chair : Hans-Rudolf Raab, DE
30' 15'	- Standard of care for Anal Canal Squamous carcinomas - Salvage surgery of Anal Canal Squamous carcinomas	Mark Saunders, UK Hans-Rudolf Raab, DE

12:30-12:45 15'	Conclusion and farewell	Chairs: Andrés Cervantes, ES
---------------------------	--------------------------------	-------------------------------------

12:45-13:45	Lunch
-------------	-------